Founga ke fakatohi ai ha sivi fakatu'utamaki 'o e koloa-pau Nitrosamine ki hono ngaohi 'o e Peptide .

Tali vave

Nitrosamine risk in peptide manufacturing is a per-product conclusion, not a category assumption. Laka hake he 100.00. 1,800 drug-product batches have been recalled in th…

Why nitrosamine risk is product-specific rather than a single universal assumption

ko ha fakafehoanaki 'o e kolomu 'e ua 'oku fakahaa'i ai ha fakakaukau 'o e tu'unga 'o e fa'ahinga 'i he tafa'aki 'e taha mo ha sivi 'o e koloa-pau 'i he tafa'aki 'e taha ., mo

'Oku tali 'a e inu 'e he vahenga CPCA: FDA vs Mo'ui 'a Kanata 'Oku tali 'a e inu 'e he vahenga CPCA: FDA vs Mo'ui 'a Kanata, hange ko ia kuo palani mei he ma'u'anga fakamatala 'oku lave ki ai .. 'Oku tali 'a e inu 'e he vahenga CPCA: FDA vs Mo'ui 'a Kanata. fakamatala pa kuo fakakulupu: Fakakalakalasi 1: FDA 26.5, Mo'ui lelei Kanata 18; Fakakalakalasi 2: FDA 100, Mo'ui lelei Kanata 100; Fakakalakalasi 3: FDA 400, Mo'ui lelei Kanata 400; Fakakalakalasi 4: FDA 1500, Mo'ui lelei Kanata 1500; Fakakalakalasi 5: FDA 1500, Mo'ui lelei 'a Kanata 1500.Ma'u'anga fakamatala: FDA CDER Nitrosamine 'uli 'oku tali 'a e ngaahi fakangatangata 'o e inu; Fakahinohino ki he Mo'ui 'a Kanata 2024-05-31. 'Oku tali 'a e inu 'e he vahenga CPCA: FDA vs Mo'ui 'a Kanata 0 500 1000 1500 2000 FDA Mo'ui lelei Kanata 26.5 18 Fa'ahinga 1 100 100 Fa'ahinga 2 400 400 Fa'ahinga 3 1500 1500 Fa'ahinga 4 1500 1500 Fa'ahinga 5 Ma'unga fakamatala: FDA CDER Nitrosamine 'uli 'oku tali 'a e ngaahi fakangatangata 'o e inu; Fakahinohino ki he Mo'ui 'a Kanata (2024-05-31)

Fakatahataha'i 'o e Polypeptide 'a e tokotaha 'oku ne 'omi Fakatahataha'i 'o e Pseudoproline 'Oku fie ma'u ha sivi fakatu'utamaki 'o e nitrosamine 'o e koloa-pau koe'uhi ko e 'inasi 'oku tali 'oku fakafalala ia 'i he fokotu'utu'u 'o e nitrosamine fakafo'ituitui ., pea 'oku fakafalala 'a e ngaahi laine fakatu'utamaki 'i he synthesis fakafo'ituitui .. Ko e fakamatala ‘a e FDA ki he founga ‘o e potency-fakafa’ahinga 'oku ne talamai 'oku makehe 'a e NDSRIs 'i he angamaheni ki he faito'o takitaha pea 'oku 'ikai ke fa'a 'i ai ha ngaahi fakamatala malu 'oku 'i ai 'oku ma'u ke fokotu'u 'a e ngaahi fakangatangata 'o e AI ., ko ia 'oku sivi'i fakafo'ituitui 'a e fokotu'utu'u takitaha 'o fakafou 'i ha saati tafe 'oku ne vahevahe ha fa'ahinga potency .. Ko e vaeua fakakona ia 'o e fakakikihi ..

Ko e vaeua 'o e founga ngaue ko e sivi 'oku 'a e tokotaha 'oku ne ma'u 'a e fakamafai'i 'o e maketi 'oku ngaue mo e API mo e kau ngaohi 'o e koloa 'osi mo 'enau kau tu'uaki 'o e raw-material ., faka'aonga'i 'a e ngaahi tefito'i mo'oni 'o e pule'i 'o e fakatu'utamaki 'o e tu'unga lelei 'o hange ko ia 'oku fokotu'u atu 'i he ICH Q9., pea ko ha fakatu'utamaki 'oku 'ilo'i 'i he API pe koloa 'osi 'oku ne fakatupu 'a e sivi fakapapau'i 'o 'ikai ha toloi ., ki he ko e naitolosamini Q ‘a e EMA .&HA (Fkh.23, Okatopa 2025). Ko hono ola ko e 'ikai lava ke 'omi ha fika 'e taha 'i he tafa'aki 'o ha portfolio peptide ..

Founga ke fakatohi ai ha sivi fakatu'utamaki 'o e koloa-pau Nitrosamine ki hono ngaohi 'o e Peptide .

'Oku kehekehe 'a e ngaahi fika 'i he pule'anga ., pea ko e divergence 'oku lahi taha ia 'i he vahenga malohi taha .. Ko e tepile ‘oku tali-faka’aonga’i ‘e he FDA ki he nitrosamines . ʻokú ne foaki 100 'o e/'aho ki he Fa'ahinga CPCA 2, 400 'o e/'aho ki he Fa'ahinga . 3, mo e 1,500 ng/'aho ki he Ngaahi Fa'ahinga 4 mo e 5, lolotonga Fakahinohino ki he nitrosamine ‘a e Mo’ui ‘a Kanata lisi Fa'ahinga 1 ʻi 18 ng/'aho mo e Ngaahi Fa'ahinga . 2 fakafou 5 ʻi 100, 400, 1,500 mo e 1,500 'o e/'aho. 'Oku malie 'a e ongo tepile mei he Fa'ahinga 1.1. 2 ki 'olunga, ko ia ko e tu'utu'uni 'aonga ke fakahingoa 'a e mafai 'i he fika kotoa pe kae 'ikai ko e 'avalisi kinautolu ..

Which peptide-manufacturing inputs can actually introduce nitrosamine risk

Mape'i 'a e malava ke fa'u mo e ngaahi hala 'o e 'uli: 'amines faingata'a'ia pe ngaahi me'a mu'omu'a ., ngaahi fakafofonga naitoloseti, tali mo e ngaahi tu'unga 'o e tanaki'anga, ngaahi naunau kuo toe ngāueʻaki, kolosi-'uli mo e 'ave 'o e nitrosamines kuo 'osi ngaohi. Ko e 'ikai ha amine 'i he koloa 'oku fakataumu'a ki ai 'oku 'ikai ke ne faka'ehi'ehi meiate ia pe 'a e 'uli 'o e nitrosamine ..

Founga ke fakatohi ai ha sivi fakatu'utamaki 'o e koloa-pau Nitrosamine ki hono ngaohi 'o e Peptide .

Ko e tafa'aki nitrosating 'o e screen ko ha lisi 'oku faka'uhinga'i .. Ko e EFPIA faito'o konatapu-me'a fakatu'utamaki-pule'i 'o e workflow . fakahingoa 'a e naitalaite hange ko e sotiume naitalaite mo e 'esiti naitolosi ., naitiki ʻokisaiti, naitolosili halaiti, taitoloseni tilaiokisaiti mo e taitoloseni tetolokisaiti ., mo e ngaahi naitaleti faka'okani hange ko e naitaliti tert-butyl .. 'Oku fakatokanga'i 'e he workflow tatau 'oku 'ikai ko e nitrite ia 'iate ia pe ko ha fakafofonga nitrosating ka 'e lava ke hoko ko ha taha 'i he ngaahi tu'unga hange ko e mitia 'esiti aqueous ., ko ha faikehekehe 'oku taau ke 'ave ki he lekooti ko ia 'oku 'ikai ke tokanga'i 'e he tokotaha vakai'i 'a e lave ki he nitrite kotoa pe ko ha ma'u 'otometiki ..

Ko e lisi 'o e faingata'a'ia-'amine ko e feitu'u ia 'oku kehekehe ai 'a e ngaahi founga 'o e peptide mei he ngaahi founga 'o e fanga ki'i-molecule .. Ko e EFPIA faito'o konatapu-me'a fakatu'utamaki-pule'i 'o e workflow . hingoa amines fakafe'iloaki ko e ngaahi me'a 'oku 'ikai ke ma'a pe degradants 'o e ngaahi me'a fakalelei'i 'o e amide DMF ., DMAc mo e NMP .; ko e ngaahi makatu'unga 'o e 'amini hono tolu 'o e trietilamini, taisopolopiletilamini (TIPEA) mo e N-metilimofolini . (NMM); ngaahi māsima ʻamoniume ʻo e tuʻunga fā hangē ko e tetalabutilamoniume polomaiti .; mo e ngaahi 'amini tefito hange ko e monoetilamini .. 'Oku ne toe faka'ilonga'i 'a e ngaahi inputs fefeka hange ko e NaCl ., NaOH, K2CO3 mo e malala 'e lava ke ne 'ave 'a e ngaahi tu'unga ppm 'o e ngaahi me'a nitrosating ., lolotonga ia ko e ngaahi reagents vai ., 'oku fakakaukau'i 'a e ngaahi fakalelei'anga 'o e 'okani mo e ngaahi fakalelei'anga 'o e vai ma'ulalo-pH 'i he angamaheni 'oku nitrite-ta'etotongi ..

Ko e founga ngaue 'oku 'ikai ko ha fakakaukau .. Ko ha vakai'i 'o e ngaahi me'a na'e hoko 'i he nitrosamine kuo fakatohi . 'oku ne fakatotolo'i 'a e NDMA 'i he valsartan ki he dimethylamine ko ha toenga 'o e 'uli 'i he DMF ., ko e NMBA mu'omu'a ki he faka'auha 'o e NMP ., mo e NDIPA mo e NEIPA ki he ngaahi koloa dealkylation 'o e DIPEA .. Ko e fakalahi 'o e WHO GMP 'i he naitolosamine . fokotu'u 'a e 'atakai 'i he tu'unga 'o e hala 'o e synthesis ., ngaahi naunau, ngaahi me'angaue mo e ngaahi me'angaue ., 'a ia ko e granularity 'oku fie ma'u 'e ha screen fakahu peptide ..

How process conditions change that risk

Ko e ngaahi tu'unga 'e tolu 'oku nau liliu ha amine lolotonga ki ha nitrosamine kuo fa'u ko ha amine faingata'a'ia ., ko ha faʻahinga naitoloseti, pea mo e ngaahi tu‘unga ‘okú ne ‘omai kinautolu ke nau fakatahataha‘í .. Ko e Ko e tokotaha tu'uaki 'o e Polypeptide fakatupu WHO GMP annex on nitrosamines states that the use of nitrite or another nitrosating agent as a quenching reagent should be avoided if vulnerable amines may be present at that or a later process step and sufficient depletion is not guaranteed, and it recommends replacing nitrites in azide decomposition quenches.

That quench step is the documented failure mode. Ko ha vakai'i 'o e ngaahi me'a na'e hoko 'i he nitrosamine kuo fakatohi . describes how unreacted azides from tetrazole formation are eliminated by adding sodium nitrite in an acidic environment, and that any alkyl amine residues from solvents, reagents or upstream contamination will likely generate associated nitrosamines during that disposition. The same review describes metformin as relatively stable and requiring co-existing nitrosating agents, moisture and heat, mo e nitrites mo e nitrates 'i he ngaahi me'a tokoni pea mo e 'uha 'o e granulation 'o e 'uha mo e vela 'o e fakamomoa 'o kamata'i 'a e nitrosation ..

'Oku 'ikai ke tu'u 'a e fakatu'utamaki 'i he hala synthesis .. Ko e naitolosamini Q ‘a e EMA .&HA (Fkh.23, Okatopa 2025) tanaki atu 'a e fakatu'utamaki 'o e nitrosamine 'a e fa'u mei he ngaahi me'a 'oku ngaue pe ko honau ngaahi me'a 'oku fekau'aki 'oku 'i ai ha amine faingata'a'ia lolotonga 'a e 'osi-koloa formulation mo e tauhi koe'uhi ko e ngaahi faka'ilonga 'o e nitrites ., pea talaange ki he kau MAH na'e 'ikai ke nau fakakaukau'i 'eni 'i he sitepu 1. 1 ke toe fakakaukauʻi ʻenau ngaahi siví pea hoko atu ki he sitepu 1.1. 2 sivi 'i he taimi 'oku taau ai. Mo ha kautaha ngaohi peptide ., 'oku 'uhinga ia ki he reagent tamate'i ., ko hono sitoikiometri, ko e pH mo e hokohoko 'o e tanaki atu 'oku lekooti 'a e ngaahi kehekehe ., pea pehē ki he fakamāfana ., tauhi mo e fakafonu. Ko ha sivi 'oku tu'u 'i he hala synthesis pea 'ikai 'aupito ke a'u ki he ngaahi sitepu ko ia 'oku ne tuku 'a e founga 'o e ta'elavame'a 'o 'ikai ke sivi'i ., which is the point at which a nitrosamine risk assessment for peptide manufacturing stops being defensible.

Does the synthesis route change the assessment

a route-selection flowchart branching from a single peptide product into solid-phase, liquid-phase and recombinant or hybrid

ʻIo, the route changes which reagent classes enter the assessment, but it does not change the assessment method. Ko e EFPIA faito'o konatapu-me'a fakatu'utamaki-pule'i 'o e workflow . partitions the amine and nitrosating-agent sources by the reagents, catalysts and solvents a given process uses, so the route determines the input list rather than the conclusion.

In SPPS, assess the actual bases, ngaahi meʻa fakamolū, impurities and recovery streams. Piperitini, commonly used for Fmoc removal, is a secondary amine; DIPEA used in coupling is a tertiary amine. Their structures and reaction pathways differ, so do not describe all deprotection and coupling bases as tertiary amines.

‘Oku toe fakapapau‘i ‘e he mape ‘o e halá pe ko hai ‘okú ne ma‘u ‘a e lekooti fē .. Bachem 'a e SPPS-pau 'a e nitrosamine fakatu'utamaki-fakafuofua'i 'a e webinar 'oku ne fokotu'u 'a e CDMO ko ha le'o matapa ki he malava ke 'uli'i 'a e nitrosamine 'i he vaha'a 'o e ngaahi naunau kamata mo e faito'o konatapu ., ‘a ia ko e interface ia ‘oku ‘i ai ‘a e ngaahi tohi ‘a e tokotaha ‘oku ne ‘omai ‘a e peptide ke ne foaki atu ‘o ma’a . Fakatahataha'i 'o e Peptoid 'o e konga fefeka ki he kautaha ngaohi koloa kuo 'osi. Ko e fakahinohino 'a e EMA ki he peptides fakatupu . 'oku ne 'omi 'a e seti 'o e ngaahi tohi 'oku 'amanaki ki ha API peptide synthetic ., kau ai 'a e ngaahi naunau kamata ., reagents mo e ngaahi me'a 'oku 'ikai ke ma'a ., ko ia 'e lava ke langa 'a e faile nitrosamine ko ha fakalahi 'o e faile CMC kae 'ikai ko ha ngaue fakafehoanaki ..

What analytical controls and confirmatory testing does the assessment require

Ko ha founga fakapapau'i 'oku fe'unga pe ia 'i he taimi 'oku tangutu ai hono fakangatangata 'o e lahi 'i he pe 'i lalo 'i he tu'unga kuo pau ke ke pule'i ., pea 'i he taimi 'oku 'ufi'ufi ai 'e hono package fakamo'oni 'a e matrix 'oku ke lele mo'oni .. I F2.(R2.) 'oku fie ma'u ke ki he ngaahi sivi 'o e 'uli 'a e QL ki he founga 'analaiso ke tatau pe 'i lalo 'i he threshold 'o e lipooti ., pea ‘oku fiema‘u ki ai ‘a e pau ., kehekehe, ofi 'aupito, repeatability mo e tonu 'o e vaha'a taimi ki ha sivi 'o e 'uli 'o e lahi .. 'Oku fakamatala'i 'e he fakahinohino tatau 'a e fakangatangata 'o e lahi ko e lahi ma'ulalo taha 'o e analyte 'i ha sipinga 'e lava ke fakapapau'i 'a e lahi 'aki 'a e tonu mo e tonu fe'unga ..

<kalasi fakatata="blog-saati" sitaila="max-lahi:640px;tafatafa'aki:1.5rem 'otometiki;lahi-mataʻitohi:12px;laine-ma'olunga:1.3;lanu:maʻu tofiʻa"> <svg vakai'i 'a e Puha="0 0 560 380" sitaila="max-lahi: 100%; ma'olunga: 'otometiki; fāmili-mataʻitohi: 'Inita', sisitemi-ui, taʻe-serif; lanu: #1e293b; --saati-fakalongolongo: #64748b;" fatongia="img" aria-fakahingoa'aki="nitrosamine-founga-ongo'i-vs-fiema'u-ngaahi fakangatangata-hingoa nitrosamine-founga-ongo'i-vs-fiema'u-ngaahi fakangatangata-desc"> <sīpinga> /* 'Oku 'ai 'e he renderer 'a e saati 'i ha iframe 'a ia ko hono 'elemeniti 'o e muimui'i 'oku 'uli'uli ., pea ko e iframe ko e fotunga kehe ia ki he saati ., ko ia naʻe fakahaaʻi ʻe he ngaahi foʻi puha tohí ko ha ngaahi fakatātā ʻuliʻuli takatakai ʻi ai . (prod 09-22). Ko e tohi 'i loto 'i he iframe 'oku mahino 'i he default .; valivali ia heni 'oku ne 'ufi'ufi 'a e 'elemeniti 'o e muimui'i ., pea 'i he taimi 'oku inline ai 'a e saati 'i hono fetongi 'oku 'ikai ke fe'unga 'eni mo ha me'a .. Tauhi e ngaahi palaketi tuliki mei he poloka ko eni .: 'oku parsed ha 'elemeniti 'o e sitaila 'i loto 'i ha SVG ko e kakano muli ., ko ia ʻoku liʻaki ʻe ha palaketi hē ʻe taha ʻa e tuʻutuʻuni kotoa pē ʻi aí .. */ html, sino { puipuitu'a: #ffffff; tafatafa'aki: 0; } @mītia (manako-fakasi'isi'i-ngaue: fakasi'isi'i) { * { moʻui: hala !mahu'inga; fakaangaanga: hala !mahu'inga; } } </sīpinga> <fakahangatonu x="0" y="0" laulahi="560" ma'olunga="380" rx="8" fakafonu="#ffffff" /> <id 'o e hingoa="nitrosamine-founga-ongo'i-vs-fie ma'u-ngaahi fakangatangata-hingoa">Nitrosamine founga ongo'i vs fie ma'u 'a e ngaahi fakangatangata .</kaveinga> <id fakamatala="nitrosamine-founga-ongo'i-vs-fie ma'u-ngaahi fakangatangata-desc">Nitrosamine founga ongo'i vs fie ma'u 'a e ngaahi fakangatangata .: ngaahi mahu'inga ki he GC-MS/MS, LC-MS/MS (ma'olalo), LC-MS/MS (ma'olunga), FDA LC-HRMS, Sitakilipitini NDSRI. Nitrosamine founga ongo'i vs fie ma'u 'a e ngaahi fakangatangata .. fakamatala pa fakahosite: GC-MS/MS 0.005; LC-MS/MS (ma'olalo) 0.01; LC-MS/MS (ma'olunga) 0.02; FDA LC-HRMS 0.05; Sitakilipitini NDSRI 0.1; Fakangatangata ki he 10.00. 300 mg/'aho 0.088.Ma'u'anga fakamatala: EMA Q&HA, Fakahā.23 2025-10-10.</fakamatala> <tohi x="280.0" y="29" tohi-taula="loto" lahi-mata'itohi="18" font-mamafa="800" fakafonu="Lanu lolotonga">Nitrosamine founga ongo'i vs fie ma'u 'a e ngaahi fakangatangata .</tohi> <laine x1="145" y1="298.0" x2="510" y2="298.0" stroke="Lanu lolotonga" opacity="0.08" /> <laine x1="145" y1="243.0" x2="510" y2="243.0" stroke="Lanu lolotonga" opacity="0.08" /> <laine x1="145" y1="188.0" x2="510" y2="188.0" stroke="Lanu lolotonga" opacity="0.08" /> <laine x1="145" y1="133.0" x2="510" y2="133.0" stroke="Lanu lolotonga" opacity="0.08" /> <laine x1="145" y1="78.0" x2="510" y2="78.0" stroke="Lanu lolotonga" opacity="0.08" /> <tohi x="136.0" y="97.5" tohi-taula="ʻosi" lahi-mata'itohi="11" fakafonu="Lanu lolotonga" opacity="0.8"><tspan x="136.0" dy="0">GC-MS/MS</tspan></tohi> <fakahangatonu x="145" y="78.0" laulahi="1.8" ma'olunga="30.0" rx="4" fakafonu="#f97316" /> <tohi x="154.8" y="97.5" lahi-mata'itohi="11" fakafonu="Lanu lolotonga">0.005</tohi> <tohi x="136.0" y="135.5" tohi-taula="ʻosi" lahi-mata'itohi="11" fakafonu="Lanu lolotonga" opacity="0.8"><tspan x="136.0" dy="0">LC-MS/MS (ma'olalo)</tspan></tohi> <fakahangatonu x="145" y="116.0" laulahi="3.6" ma'olunga="30.0" rx="4" fakafonu="#38bdf8." /> <tohi x="156.7" y="135.5" lahi-mata'itohi="11" fakafonu="Lanu lolotonga">0.01</tohi> <tohi x="136.0" y="173.5" tohi-taula="ʻosi" lahi-mata'itohi="11" fakafonu="Lanu lolotonga" opacity="0.8"><tspan x="136.0" dy="0">LC-MS/MS (ma'olunga)</tspan></tohi> <fakahangatonu x="145" y="154.0" laulahi="7.3" ma'olunga="30.0" rx="4" fakafonu="#a78bfa" /> <tohi x="160.3" y="173.5" lahi-mata'itohi="11" fakafonu="Lanu lolotonga">0.02</tohi> <tohi x="136.0" y="211.5" tohi-taula="ʻosi" lahi-mata'itohi="11" fakafonu="Lanu lolotonga" opacity="0.8"><tspan x="136.0" dy="0">FDA LC-HRMS</tspan></tohi> <fakahangatonu x="145" y="192.0" laulahi="18.2" ma'olunga="30.0" rx="4" fakafonu="#22c55e" /> <tohi x="171.2" y="211.5" lahi-mata'itohi="11" fakafonu="Lanu lolotonga">0.05</tohi> <tohi x="136.0" y="249.5" tohi-taula="ʻosi" lahi-mata'itohi="11" fakafonu="Lanu lolotonga" opacity="0.8"><tspan x="136.0" dy="0">Sitakilipitini</tspan><tspan x="136.0" dy="12">NDSRI</tspan></tohi> <fakahangatonu x="145" y="230.0" laulahi="36.5" ma'olunga="30.0" rx="4" fakafonu="#fofonga15" /> <tohi x="189.5" y="249.5" lahi-mata'itohi="11" fakafonu="Lanu lolotonga">0.1</tohi> <tohi x="136.0" y="287.5" tohi-taula="ʻosi" lahi-mata'itohi="11" fakafonu="Lanu lolotonga" opacity="0.8"><tspan x="136.0" dy="0">Fakangatangata ki he 300</tspan><tspan x="136.0" dy="12">mg/'aho</tspan></tohi> <fakahangatonu x="145" y="268.0" laulahi="32.1" ma'olunga="30.0" rx="4" fakafonu="#fb7185" /> <tohi x="185.1" y="287.5" lahi-mata'itohi="11" fakafonu="Lanu lolotonga">0.088</tohi> <tohi x="280.0" y="366" tohi-taula="loto" lahi-mata'itohi="10" fakafonu="ʻemau(--saati-fakalongolongo, Lanu lolotonga)">Ma'unga fakamatala: EMA Q&HA, EMA/409815/2020 Fakaha.23 (2025-10-10)</tohi> </svg> </fōtunga>

Mo e AI 'i he ng/'aho mo e lahi taha 'o e tu'unga faka'aho M 'i he mg/'aho ., 'Oku 'omi 'e he AI/M ha tokanga 'i he ng/mg ., tatau fakafika mo e ppm .. Fakahaa'i 'i he ppb ., fakalahi ʻa e mahuʻinga ko iá ʻaki ʻa e . 1,000. 'Iuniti 'o e pule'anga mahino mo faka'aonga'i 'a e ngaahi tu'utu'uni lolotonga 'o e pule'anga-pau ki he nitrosamines lahi ., li'aki pe fakasi'isi'i 'a e sivi ..

'Oku 'oatu 'e he fakahoko 'o e founga pulusi 'a e benchmark 'o e ngaahi 'atakai .. HA 2025 vakai'i 'o e ngaahi founga 'analaiso nitrosamine 'oku ne fakatahataha'i 'a e ngaahi founga vakai'i 'o e LC-MS/MS 'i he . 0.05 ppm, GC-MS/MS ngaahi founga 'oku ma'ulalo 'o hange ko e . 0.001 ppm, mo ha founga FDA LC-HRMS 'i he . 1 'o e/mL, mo e NDMA mo e NDEA takatakai 'i he 2019. 0.1 ki 0.5 ng/mL 'i ha 5 mg/mL sipinga 'o e makatu'unga. Ko e ngaahi fika ko iá 'oku ha'u ia mei he API 'o e molekula si'isi'i mo e matrices sartan ., ko ia ko e ngaahi fakafuofua kinautolu ., 'ikai ko e fakahoko 'o e peptide .: peptide-matrix LOQ 'oku fakafalala ia 'i he ngaahi ola 'o e matrix, sipinga 'o e teuteu mo e polarity 'o e taumu'a ., and no published nitrosamine LOQ measured in a peptide drug-substance matrix was located for this article. State the matrix with every LOQ you cite.

Testing cadence follows the risk conclusion. Ko e naitolosamini Q ‘a e EMA .&HA (Fkh.23, Okatopa 2025) sets testing at 10% of annual batches or 3 per year, ko e fē ʻoku māʻolunga angé ., where the source of risk is understood and levels are consistent batch to batch, and requires all batches to be tested where fewer than three are made annually. The MHRA’s list of common nitrosamine submission gaps names inadequate sensitivity of analytical methods and incomplete risk evaluation among the defects it rejects, which is why the nitrosamine risk evaluation checklist should carry the method’s LOQ, its matrix and its validation status as separate line items.

What records make the conclusion auditable for a client audit or regulator

The record set that survives an audit is the one that mirrors the official template fields, because that is what a reviewer compares against. The CMDh nitrosamine risk-evaluation template requires the MAH name and address; the product type; the product and API or intermediate name; the marketing authorisation number; the EU procedure number for MRP or DCP products; the API manufacturer name and address; the finished-product manufacturer name and address; the confirmatory-testing timeline; plus a risk classification of high, moderate or low and a root-cause category covering manufacturing or cross-contamination, product formulation or stability, product synthesis, and in-vivo formation. A peptide supplier’s file should be able to populate every one of those fields for the API portion.

Ko e ngaahi fakataha'anga 'o e ngaahi tohi 'oku ne 'ai 'a e ngaahi mala'e ko ia ke malu'i ko e ngaahi me'a tatau pe ia 'oku faka'aonga'i ki ha fa'ahinga lekooti 'o e kulupu .. Ko ha tohi fakamo'oni 'o e 'analaiso 'oku totonu ke vakai'i ko ha lekooti 'o e batch-pau kae 'ikai ko ha fakamatala fakamaketi fakalukufua ., pea ko ha peseti ma‘a pē ‘oku ‘ikai ke ne fokotu‘u ‘a e ‘ulungaanga kakato ‘o e me‘a fakataha‘í .: maʻa, tohi fakamo'oni fakatāutaha, founga, fika 'o e lot mo e ngaahi tohi 'oku totonu ke sivi'i fakataha. Ko e fakalahi 'o e WHO GMP 'i he naitolosamine . tānaki atu ‘a e ngaahi lekooti ‘o e supply-chain ‘okú ne ‘amanekina ke tauhi ., kau ai e hingoa 'o e kautaha ngaohi 'o e raw-material mo hono tu'uaki, ko e ngaahi fatongia 'o e kau ngaohi mo'oni ., pea mo ha kau repackers mo e kau tufaki'anga koloa 'oku nau tokanga'i 'a e ngaahi naunau kimu'a pea toki ngaohi 'a e API ..

'Oku 'ikai ke tapuni 'e he pepa 'a e kau tu'uaki 'a e fehu'i 'iate ia pe .. Fakahinohino ki he nitrosamine ‘a e Mo’ui ‘a Kanata 'oku ne fakaha 'oku 'ikai ko ha fetongi 'o e ngaahi fakaha 'a e kau ngaohi mo e kau tu'uaki 'o ha sivi fakatu'utamaki fakakatoa 'oku fefeka 'e he MAH ., mo e ko e naitolosamini Q ‘a e EMA .&HA (Fkh.23, Okatopa 2025) 'oku ne fokotu'u 'a e fatongia ki he MAH ke ngaue mo e kau tu'uaki API ke fakapapau'i 'oku tali 'a e tu'unga lelei 'o e API ., kau ai 'a e ngaahi fakangatangata 'o e amine fefeka ange 'i he monokalafi pharmacopoeial 'a ia 'oku fie ma'u ai kinautolu 'e he koloa 'osi .. Ko e fakaha 'o e kautaha ko ha input ia ki he faile ., ‘ikai ko e fakamulituku ia ..

When is confirmatory testing required versus when does a documented negative assessment close the question

ko ha konga fakamatala 'o ha tepile 'o e faile fakatu'utamaki 'oku fakahaa'i ai 'a e laine fakatu'utamaki 'e taha kuo fakakakato mei he naunau 'o e input 'o fakafou 'i he fika 'o e lot ., tokotaha tu'uaki koloa
<kalasi fakatata="blog-saati" sitaila="max-lahi:640px;tafatafa'aki:1.5rem 'otometiki;lahi-mataʻitohi:12px;laine-ma'olunga:1.3;lanu:maʻu tofiʻa"> <svg vakai'i 'a e Puha="0 0 560 380" sitaila="max-lahi: 100%; ma'olunga: 'otometiki; fāmili-mataʻitohi: 'Inita', sisitemi-ui, taʻe-serif; lanu: #1e293b; --saati-fakalongolongo: #64748b;" fatongia="img" aria-fakahingoa'aki="fakapapau'i-sivi-kavenga-'i he taimi-'oku-'ilo'i-'a e fakatu'utamaki-hingoa fakapapau'i-sivi-kavenga-'i he taimi-'oku-'ilo'i ai 'a e fakatu'utamaki-desc"> <sīpinga> /* 'Oku 'ai 'e he renderer 'a e saati 'i ha iframe 'a ia ko hono 'elemeniti 'o e muimui'i 'oku 'uli'uli ., pea ko e iframe ko e fotunga kehe ia ki he saati ., ko ia naʻe fakahaaʻi ʻe he ngaahi foʻi puha tohí ko ha ngaahi fakatātā ʻuliʻuli takatakai ʻi ai . (prod 09-22). Ko e tohi 'i loto 'i he iframe 'oku mahino 'i he default .; valivali ia heni 'oku ne 'ufi'ufi 'a e 'elemeniti 'o e muimui'i ., pea 'i he taimi 'oku inline ai 'a e saati 'i hono fetongi 'oku 'ikai ke fe'unga 'eni mo ha me'a .. Tauhi e ngaahi palaketi tuliki mei he poloka ko eni .: 'oku parsed ha 'elemeniti 'o e sitaila 'i loto 'i ha SVG ko e kakano muli ., ko ia ʻoku liʻaki ʻe ha palaketi hē ʻe taha ʻa e tuʻutuʻuni kotoa pē ʻi aí .. */ html, sino { puipuitu'a: #ffffff; tafatafa'aki: 0; } @mītia (manako-fakasi'isi'i-ngaue: fakasi'isi'i) { * { moʻui: hala !mahu'inga; fakaangaanga: hala !mahu'inga; } } </sīpinga> <fakahangatonu x="0" y="0" laulahi="560" ma'olunga="380" rx="8" fakafonu="#ffffff" /> <id 'o e hingoa="fakapapau'i-sivi-kavenga-'i he taimi-'oku-fakatu'utamaki-'oku-'ilo'i-hingoa">Kavenga sivi fakapapau'i 'i he taimi 'oku 'ilo'i ai 'a e fakatu'utamaki .</kaveinga> <id fakamatala="fakapapau'i-sivi-kavenga-'i he taimi-'oku-fakatu'utamaki-'oku-'ilo'i-desc">Ko e feitu'u 'oku 'ilo'i ai 'a e fakatu'utamaki ., 'Oku 'amanaki ke sivi 'a e EMA 'i he 'aho 2019. 10% of annual batches or 3 per year, ko e fē ʻoku māʻolunga angé ., pea mo e ngaahi kulupu kotoa pe 'i he taimi 'oku si'i hifo ai 'i he 100. 3 ‘oku fai fakata‘u .. Kavenga sivi fakapapau'i 'i he taimi 'oku 'ilo'i ai 'a e fakatu'utamaki .. fakamatala lolipop: Si'i hifo 'i he 100. 3 ngaahi kulupu/ta'u 3; 10% 'o e ngaahi kulupu fakata'u 10; Si'isi'i taha 'i he ta'u 3.Ma'u'anga fakamatala: EMA Q&HA, EMA/409815/2020 Fakaha.23, F&HA 8 2025-10-10.</fakamatala> <tohi x="280.0" y="29" tohi-taula="loto" lahi-mata'itohi="18" font-mamafa="800" fakafonu="Lanu lolotonga">Kavenga sivi fakapapau'i 'i he taimi 'oku 'ilo'i ai 'a e fakatu'utamaki .</tohi> <laine x1="145" y1="298.0" x2="510" y2="298.0" stroke="Lanu lolotonga" opacity="0.08" /> <laine x1="145" y1="243.0" x2="510" y2="243.0" stroke="Lanu lolotonga" opacity="0.08" /> <laine x1="145" y1="188.0" x2="510" y2="188.0" stroke="Lanu lolotonga" opacity="0.08" /> <laine x1="145" y1="133.0" x2="510" y2="133.0" stroke="Lanu lolotonga" opacity="0.08" /> <laine x1="145" y1="78.0" x2="510" y2="78.0" stroke="Lanu lolotonga" opacity="0.08" /> <tohi x="136.0" y="118.7" tohi-taula="ʻosi" lahi-mata'itohi="11" fakafonu="Lanu lolotonga" opacity="0.8"><tspan x="136.0" dy="0">Si'i hifo he 3 .</tspan><tspan x="136.0" dy="12">ngaahi kulupu/ta'u</tspan></tohi> <laine x1="145" y1="114.7" x2="254.5" y2="114.7" stroke="Lanu lolotonga" opacity="0.15" stroke-lahi="1" /> <siakale cx="254.5" cy="114.7" r="6" fakafonu="#f97316" /> <tohi x="266.5" y="118.7" lahi-mata'itohi="11" fakafonu="Lanu lolotonga">3</tohi> <tohi x="136.0" y="192.0" tohi-taula="ʻosi" lahi-mata'itohi="11" fakafonu="Lanu lolotonga" opacity="0.8"><tspan x="136.0" dy="0">10% 'o e ta'u .</tspan><tspan x="136.0" dy="12">ngaahi kulupu</tspan></tohi> <laine x1="145" y1="188.0" x2="510.0" y2="188.0" stroke="Lanu lolotonga" opacity="0.15" stroke-lahi="1" /> <siakale cx="510.0" cy="188.0" r="6" fakafonu="#38bdf8." /> <tohi x="522.0" y="192.0" lahi-mata'itohi="11" fakafonu="Lanu lolotonga">10</tohi> <tohi x="136.0" y="265.3" tohi-taula="ʻosi" lahi-mata'itohi="11" fakafonu="Lanu lolotonga" opacity="0.8"><tspan x="136.0" dy="0">Si'isi'i taha 'i he ta'u</tspan></tohi> <laine x1="145" y1="261.3" x2="254.5" y2="261.3" stroke="Lanu lolotonga" opacity="0.15" stroke-lahi="1" /> <siakale cx="254.5" cy="261.3" r="6" fakafonu="#a78bfa" /> <tohi x="266.5" y="265.3" lahi-mata'itohi="11" fakafonu="Lanu lolotonga">3</tohi> <tohi x="280.0" y="366" tohi-taula="loto" lahi-mata'itohi="10" fakafonu="ʻemau(--saati-fakalongolongo, Lanu lolotonga)">Ma'unga fakamatala: EMA Q&HA, EMA/409815/2020 Fakaha.23, F&HA 8 (2025-10-10)</tohi> </svg> </fōtunga>

'Oku fie ma'u 'a e sivi fakapapau'i 'i he taimi 'oku 'ilo'i ai 'e he sivi'i 'o e fakatu'utamaki ha fakatu'utamaki ., pea ‘oku ‘ikai ke ‘amanaki ia ‘i he taimi ‘e faka‘osi‘aki ai ‘e he sivi ‘oku ‘ikai ke ‘ilo‘i ha fakatu‘utāmaki .. Fakahinohino ki he nitrosamine ‘a e Mo’ui ‘a Kanata ‘oku pehē ‘oku ‘ikai ‘amanaki ke fai ha sivi fakapapau ‘i he feitu‘u ‘oku faka‘osi‘aki ai ‘e he sivi‘i ‘o e fakatu‘utāmakí ‘oku ‘ikai ke ‘ilo‘i ha fakatu‘utāmaki ., mo e ko e naitolosamini Q ‘a e EMA .&HA (Fkh.23, Okatopa 2025) fokotu'u 'a e trigger 'i he tafa'aki 'e taha .: kapau 'oku 'ilo'i ha fakatu'utamaki 'i he API pe ko e koloa kuo 'osi ., kuo pau ke fakahā ‘e he MAH ki he kau ma‘u mafai ‘oku nau ma‘ú pea hoko atu ‘o ‘ikai toe toloi ‘a e ngaahi sivi fakamo‘oní ..

'E lava ke fe'unga ha fakamulituku 'oku 'ikai ha fakatu'utamaki kuo fakatohi 'i he taimi 'oku poupou'i ai 'e he sivi kakato 'o e koloa mo e founga ngaue .. Lekooti e ngaahi fakakaukau ., fakamo'oni 'a e kau tu'uaki, pule'i 'o e 'uli, fa'u mo e fakakaukau fakama'a ., mo e ngaahi liliu te ne toe fakaava 'a e sivi .; ko ha screen amine kovi tokotaha pe 'oku 'ikai fe'unga .. Fakatahataha'i 'o e Peptide 'o e Spot

Confirmatory and reduced-testing decisions depend on the applicable guidance, measured levels, process understanding and consistency. Do not treat a low AI fraction or a single absent precursor as unconditional permission to omit controls. Record the guideline version and the evidence satisfying each condition.

Ngaahi Fehuʻi ʻOku Faʻa ʻEke

Does every peptide need confirmatory nitrosamine testing?

Testing follows the documented product-specific risk evaluation and applicable regulatory expectations. The presence of an amine alone neither proves nitrosamine formation nor automatically determines testing. Assess amine susceptibility, nitrosating sources, process conditions, ngaahi meʻa ʻuli, formulation and storage; review the conclusion when relevant information changes. Peptide Wholesale Supplier

Which acceptable intake limit should a peptide manufacturer cite?

The one in force in the jurisdiction the file is written for, named alongside the number. Limits are not harmonised at the low end. Tepile CPCA ‘a e Mo’ui ‘a Kanata seti Fa'ahinga 1 ʻi 18 'o e/'aho, lolotonga Ko e tepile ‘oku tali-faka’aonga’i ‘e he FDA ki he nitrosamines . ʻoku fakaʻaongaʻi 26.5 ng/aho ki he vahenga tatau .. Ngaahi fa'ahinga 2 fakafou 5 lototaha ki he 100, 400, 1,500 mo e 1,500 'o e/'aho. Faka'avalisi 'o e ongo Fa'ahinga . 1 'e hala 'a e ngaahi mahu'inga; fili 'a e pule'anga 'oku ne pule'i 'a e koloa pea talamai ia 'i he faile .. Ko e feitu'u 'oku 'i ai ai ha ongo naitolosamine ., Ko e tu’utu’uni fakangatangata fakalukufua ‘a e Mo’ui ‘a Kanata ‘oku ne fakangatangata ‘a e NDMA mo e NMBA ‘i he 100.000. 96.0 'o e/'aho mo e NDMA pea mo e NDEA mo e . 26.5 'o e/'aho, ko ia ko e fika 'o e 'uli 'e taha 'oku 'ikai ko e fika'i kotoa ia ..

Ko e hā hono lahi ʻo e ongoʻi ʻoku fie maʻu ke hoko ha founga nitrosamine .?

Sensitive fe'unga ke fakahaa'i 'a e tu'unga 'oku tangutu 'i lalo 'i he threshold 'oku fakafalala ki ai 'a e sivi ., 'a ia ko ha konga 'o ha fakangatangata 'o e koloa-pau kae 'ikai ko e fakangatangata 'iate ia pe .. I F2.(R2.) 'oku fie ma'u 'a e fakangatangata 'o e lahi 'o ha founga 'o e 'uli 'o e lahi ke 'i he pe 'i lalo 'i he threshold 'o e lipooti ., pea 'oku ne fakamatala'i 'a e fakangatangata ko ia ko e lahi ma'ulalo taha 'oku lava ke fakapapau'i 'aki 'a e tonu mo e tonu fe'unga .. 'Oku a'u 'a e ngaahi founga nitrosamine kuo pulusi ki he ngaahi fakangatangata 'o e lahi 'i he ngaahi konga ma'ulalo-ki he-piliona 'o e ngaahi me'a ., ka ko e ngaahi fika ko iá ‘oku ha‘u ia mei he ngaahi matrices ‘o e fanga ki‘i molekula .. Na'e 'ikai ke ma'u ha fakatata 'o e peptide-matrix ., ko ia kuo pau ke fakahaa’i ‘a e ongo’i ‘i he matrix ‘a e kautaha ngaohi ‘o e koloa kae ‘ikai ko e no mei he ngaahi tohi ..

'Oku fe'unga nai ha fakaha 'a e kautaha fakatau ke tapuni ha laine fakatu'utamaki .?

ʻIkai. Ko e fakaha ko e input ia ki he sivi ., ‘ikai ko ha fetongi ia .. Fakahinohino ki he nitrosamine ‘a e Mo’ui ‘a Kanata ‘oku pehē ai ‘oku ‘ikai ke fetongi ‘e he ngaahi fakahā ‘a e kautaha ngaohí mo e kau tu‘uaki koloá ‘a e sivi fakatu‘utāmaki mālohi ‘a e kautaha ngaohí tonu ., mo e ko e fakalahi 'o e WHO GMP 'i he naitolosamini . 'oku fie ma'u ke 'atita'i 'a e ngaahi supply chain ki he ngaahi naunau 'oku 'i he tu'unga fakatu'utamaki. 'Oku 'ikai lava ke lau 'a e fakamatala 'o e nitrite 'o e kautaha tu'uaki ko ha fakangatangata fakalukufua pe .: Capsugel’s koloa-pau nitrosamine fakatu'utamaki-pule'i 'a e fanongonongo 'oku fakatokanga'i 'e he liliu 'o ha me'akai 'oku tali ki ha koloa-pau 'a e fakangatangata 'o e tokanga 'oku fakafalala ia 'i he fa'unga ., ko ia 'oku 'uhinga 'a e fika nitrite tatau ki he ngaahi me'a kehekehe 'i he ngaahi founga kehekehe ..

Ko e fē taimi ʻe fakaʻosi ai ʻa e tānaki ʻo e naitolosamini ʻo e ICH M7 .?

Ko ha taumuʻa palani-ngāue ʻoku ʻikai ko ha ʻaho ohi ʻoku fakapapauʻi .. Vakai'i 'a e tu'unga lolotonga 'o e tokanga'i 'o e ICH M7 mo e fakahinohino fakavahefonua nitrosamine 'oku faka'aonga'i 'i he taimi 'oku palani ai 'a e sivi ..

Aofangatuku

Kamata mei he koloa mo e hala ., pea fa'u leva 'a e mape, 'uli'i, carryover mo e ngaahi hala tauhi'anga koloa. Sivi'i 'a e ngaahi pule mo e fakamo'oni 'analaiso 'oku fie ma'u ke poupou'i 'a e fakamulituku takitaha ., fakatohi 'a e toenga 'o e ta'epau pea fokotu'u 'a e ngaahi fakatupu 'o e toe sivi.

Ko e seti lekooti ko e me'a ia 'oku ne 'ai 'a e fakamulituku ke mo'ui 'a e vakai'i .. The CMDh nitrosamine risk-evaluation template 'oku ne fakamatala'i 'a e ngaahi mala'e ., mo e Fakahinohino ki he nitrosamine ‘a e Mo’ui ‘a Kanata 'oku ne fakamatala'i 'a e fakangatangata 'o e me'a 'e lava ke 'ave 'e he ngaahi pepa 'a e kau tu'uaki .. Langa 'a e lisi 'o e sivi'i 'o e fakatu'utamaki 'o e nitrosamine 'o takatakai 'i he ngaahi mala'e ko ia ., tauhi ‘a e founga ‘o e LOQ mo e matrix ‘oku fakapipiki ki he laine fakatu’utamaki ‘oku ne tapuni ., and label the jurisdiction on every acceptable-intake figure you cite.

Two limits are worth stating plainly. This framework documents a risk conclusion for chemically synthesized peptides; it does not replace a product-specific toxicological assessment. And no published nitrosamine LOQ measured in a peptide drug-substance matrix was located for this article, so method sensitivity has to be established in your own matrix rather than adopted from a small-molecule benchmark. Sitepu hokó: map your current peptide portfolio against the input screen and identify which products have an amine and a nitrosating partner in the same process stream.


Pulusi: MOL Changes. Fakafo'ou 15 Okatopa 2026. ‘Oku ‘analaiso ‘e he fakamatala ko ení ‘a e ngaahi ma‘u‘anga fakamatala fakapule‘anga kuo lave ki aí pea ‘oku ‘omai ai ha fa‘unga palani .. 'Oku 'ikai ke ne lipooti ha 'atita tau'ataina 'o e kautaha fakatau pe ko ha ako 'uluaki 'o e fale fakatotolo fakakemi 'o e ngaahi liliu 'o e MOL ..

Fakahā fakakomesiale: 'Oku 'omi 'e he MOL Changes 'a e ngaahi ngaue peptide pea 'oku 'i ai 'ene manako fakakomesiale 'i he kaveinga ko 'eni .. 'Oku totonu ke fakapapau'i 'a e malava 'o e poloseki-pau mo e 'analaiso 'o e 'atakai 'o fakafepaki'i 'a hono faka'aonga'i 'oku fakataumu'a ki ai mo ha fakamatala fakaikiiki kuo tohi ..

Pingiani Gao

Pingiani Gao

Tekinisia 'o e tu'unga lelei mo e 'analaiso Taukei Tefito: Ko hono fakamavahe'i mo hono faka'ilonga'i 'o e ngaahi me'a 'oku 'ikai ke ma'u, HPLC/MS founga fakalakalaka ., 'analaiso 'o e ma'a 'o e chiral, pea mo e muimui ki he ngaahi tohi faito‘o fakavaha‘apule‘angá ..

Fakamatala fakatāutaha: Ko Bingyan Gao ko e “le'o matapa faka'osi” 'o e ma'a mo e tu'unga lelei 'o e peptide .. 'Oku ne taukei 'i hono faka'aonga'i 'o e ngaahi me'angaue 'analaiso kehekehe 'o e tu'unga ma'olunga pea 'oku makehe 'i hono fakatupulaki 'o e ngaahi founga mavahe chromatographic customized ki he peptides fakalelei'i faingata'a 'aupito .. Kuo ne fokotu'u ha founga profiling 'uli fefeka 'oku 'ikai ngata pe 'i hono fakapapau'i 'a e ma'a 'o e koloa 'o e . 99% pe ma'olunga ange ka 'oku ne toe 'ilo'i pau mo fakangata 'a e ngaahi 'uli 'o e ngaahi faka'ilonga 'e lava ke ne fakatupu 'a e immunogenicity .. 'I he mahino loloto 'o e FDA mo e EMA ngaahi fie ma'u fakatonutonu ki he faito'o konatapu peptide ., 'oku ne fakapapau'i 'oku 'alu fakataha 'a e kulupu kotoa pe 'oku tukuange mei he fale ngaue mo ha Tohi Fakamo'oni 'o e 'Analaiso 'oku kakato mo fakamafai'i . (COA).

Sivi'i 'a e Mo'oni & Ngaahi Fakahinohino Faka-ʻEtita
Toe vakaiʻi ʻe he .: Kau Mataotao ʻi he Kaveingá
Vahevahe 'a e fakamatala ko 'eni .
Api Kumi Whatsapp Ngaahi Sevesi Koloa